|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A61K 31/223 | (2006.01) |
| A61K 31/573 | (2006.01) |
| (11) | Number of the document | 3383385 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16805792.5 |
| Date of filing the European patent application | 2016-12-01 | |
| (97) | Date of publication of the European application | 2018-10-10 |
| (45) | Date of publication and mention of the grant of the patent | 2020-07-29 |
| (46) | Date of publication of the claims translation | 2020-12-28 |
| (86) | Number | PCT/EP2016/079511 |
| Date | 2016-12-01 |
| (87) | Number | WO 2017/093443 |
| Date | 2017-06-08 |
| (30) | Number | Date | Country code |
| 201521217 | 2015-12-01 | GB |
| (72) |
LINDBERG, Jakob, SE
|
| (73) |
Oncopeptides Innovation AB,
Luntmakargatan 46, 111 37 Stockholm,
SE
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Melflufeno dozavimo režimas vėžio atveju |
| MELFLUFEN DOSAGE REGIMENS FOR CANCER |
| Payment date | Validity (years) | Amount | |
| 2024-10-24 | 9 | 208.00 EUR |
| 2025-12-01 |